Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers

Ylisirniö, 1999, Serum type I collagen degradation markers, ICTP and crosslaps, are factors for poor survival in lung cancer, Anticancer. Res., 19, 5577

Curran, 1999, Matrix metalloproteinases in tumour invasion and metastasis, J. Pathol., 189, 300, 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C

Chambers, 1997, Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Canc. Inst., 89, 1260, 10.1093/jnci/89.17.1260

Fujimoto, 1996, Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analysis, Biochem. J., 313, 827, 10.1042/bj3130827

Strongin, 1995, Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331

Kähäri, 1999, Matrix metalloproteinases and their inhibitors in tumour growth and invasion, Ann. Med., 31, 34, 10.3109/07853899909019260

Gomez, 1997, Tissue inhibitors of metalloproteinases: structure, regulation and biological functions, Eur. J. Cell Biol., 74, 111

Miyagi, 1995, Marked induction of gelatinases, especially type B, in host fibroblasts by human ovarian cancer cells in anthymic mice, Clin. Exp. Metastasis, 13, 89, 10.1007/BF00133613

Westerlund, 1997, Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2), Gyn. Oncology., 67, 76, 10.1006/gyno.1997.4808

Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7

Itoh, 1998, Reduced angiogenesis and tumour progression in gelatinase A-deficient mice, Cancer Res., 58, 1048

Brooks, 1998, Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity, Cell, 92, 391, 10.1016/S0092-8674(00)80931-9

Hibner, 1998, BAY 12-9566, a noverl, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties, Proc. Am. Assoc. Cancer Res., 39, A2063

Kurizaki, 1998, Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma, Oncol. Rep., 5, 673

Mach, 1999, T-lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40 l-dependent mechanism: implications for tubule formation, Am. J. Pathol., 154, 229, 10.1016/S0002-9440(10)65269-8

Lamoreaux, 1998, Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro, Microvasc. Res., 55, 29, 10.1006/mvre.1997.2056

Mohan, 2000, Curcuminoids inhibit the angiogenetic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B, J. Biol. Chem., 275, 10405, 10.1074/jbc.275.14.10405

Amorino, 1998, Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production, Am. J. Pathol., 152, 199

Patterson, 1997, Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9), J. Biol. Chem., 272, 28823, 10.1074/jbc.272.46.28823

O'Reilly, 1999, Regluation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance, J. Biol. Chem., 274, 29568, 10.1074/jbc.274.41.29568

Talvensaari-Mattila, 1998, MMP-2 immunocreative protein, a marker of aggressiveness in breast carcinoma, Cancer, 83, 1153, 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4

Scorilas, 2001, Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients, Br. J. Cancer, 84, 1488, 10.1054/bjoc.2001.1810

Mirza, 2002, Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years, Ann. Surg., 235, 10, 10.1097/00000658-200201000-00003

Gasparini, 2001, Clinical significance of determination of surrogate markers of angiogenesis in breast cancer, Crit. Rev. Oncol. Hematol., 37, 97, 10.1016/S1040-8428(00)00105-0

Daidone, 1991, Laminin receptors, collagenase IV and prognosis in node negative breast cancers, Int. J. Cancer, 48, 529, 10.1002/ijc.2910480409

Talvensaari-Mattila, 1999, MMP-2 positivity and age less than 40 years increase the risk for recurrence in premenopausal patients with node-positive breast carcinoma, Breast Cancer Res. Treatm., 58, 287, 10.1023/A:1006326513176

Talvensaari-Mattila, 2001, Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast cardinoma treated with antiestrogen adjuvant therapy, Breast Cancer Res. Treatm., 65, 55, 10.1023/A:1006458601568

Hirvonen, 2003, Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma, Breast Cancer Res. Treat., 77, 85, 10.1023/A:1021152910976

Talvensaari-Mattila, 2003, Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma, Br. J. Cancer, 89, 1270, 10.1038/sj.bjc.6601238

Sivula, 2005, Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer, Breast Cancer Res. Treat., 10.1007/s10549-004-0714-4

Leppä, 2004, A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma, Clin. Cancer Res., 10, 1057, 10.1158/1078-0432.CCR-03-0047

Remacle, 1998, Assay of matrix metalloproteinase types 1, 2, 3 and 9 in breast cancer, Br. J. Cancer, 77, 926, 10.1038/bjc.1998.153

Talvensaari-Mattila, 2005, Preoperative serum MMP-9 level is prognostic in breast carcicnoma, Cancer Lett., 217, 237, 10.1016/j.canlet.2004.06.056

Ranuncolo, 2003, Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessement of prognosis in breast cancer patients, Int. J. Cancer, 106, 745, 10.1002/ijc.11288

Gianell, 2002, Gelatinase levels in male and female breast cancer, Biochem. Biophys. Res. Commun., 292, 161, 10.1006/bbrc.2002.6599

Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322

Van't Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a

Hansen Ree, 1997, High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis, Clin. Cancer Res., 3, 1623

Nakopoulou, 2002, Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis, J. Pathol., 197, 307, 10.1002/path.1129

McCarthy, 1999, High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast carcinoma, Int. J. Cancer, 84, 44, 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P

Remacle, 2000, High levels of TIMP-2 correlate with adverse prognosis in breast cancer, Int. J. Cancer, 89, 118, 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8

Visscher, 1994, Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence, Int. J. Cancer, 59, 339, 10.1002/ijc.2910590308

Nakopoulou, 2002, Correlation of tissue inhibitor of metalloproteainse-2 with proliferative activity and patients' survival in breast cancer, Mod. Pathol., 15, 26, 10.1038/modpathol.3880486

Kuvaja, 2005, The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1) but not for TIMP-2 protein is associated with a favourable prognosis in aggressive breast carcinoma, Oncology, 10.1159/000086774

Holten-Andersen, 2000, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels is associated with short survival of patients with colorectal cancer, Clin. Cancer Res., 6, 4292

Talvensaari-Mattila, 2005, High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma, Breast Cancer Res. Treatm., 89, 29, 10.1007/s10549-004-1006-8

Fishman, 1997, Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells, Cancer, 8, 1457, 10.1002/(SICI)1097-0142(19971015)80:8<1457::AID-CNCR13>3.0.CO;2-4

Autio-Harmainen, 1993, Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors, Lab. Invest., 63, 312

Young, 1995, A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2, J. Biol. Chem., 270, 999, 10.1074/jbc.270.3.999

Naylor, 1994, Expression and activity of MMPs and their regulators in ovarian cancer, Int. J. Cancer, 58, 50, 10.1002/ijc.2910580110

Takemura, 1994, Type IV collagenase and tissue inhibtor of metalloproteinase in ovarian cancer tissue, Int. J. Gyn. Obstet., 46, 303, 10.1016/0020-7292(94)90410-3

Garzetti, 1995, Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: clinical and prognostic implications, Anticancer Res., 15, 2799

Westerlund, 1999, Gelatinase A immunoreactive protein in ovarian lesions—prognostic value in epithelial ovarian cancer, Gynecol. Oncol., 79, 91, 10.1006/gyno.1999.5533

Davidson, 1999, High levels of MMP-2, MMP-9 MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma, Clin. Exp. Metastasis, 17, 799, 10.1023/A:1006723011835

Inoue, 1997, Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma, J. Obst. Gynaec. Res., 23, 139, 10.1111/j.1447-0756.1997.tb00822.x

Talvensaari-Mattila, 1999, Matrix metalloproteinase 2 immunocreative protein appears early in cervical epithelial dedifferentiation, Gynecol. Oncol., 72, 306, 10.1006/gyno.1998.5157

Davidson, 1999, MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization, Gynecol. Oncol., 73, 372, 10.1006/gyno.1999.5381

Davidson, 1999, Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix—clinicopathologic study using immunohistochemistry and mRNA in situ hybridization, Gynecol. Oncol., 72, 380, 10.1006/gyno.1998.5285

Iurlaro, 1999, Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma, Eur. J. Clin. Invest., 29, 793, 10.1046/j.1365-2362.1999.00532.x

Määttä, 2000, Localization of MT1-MMP, TIMP-1, TIMP-2 and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentation, Am. J. Clin. Pathol., 114, 402, 10.1093/ajcp/114.3.402

Moser, 1999, Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer, Anticancer Res., 19, 2365

Aglund, 2005, Gelatinase A and B (MMP-2 and MMP-9) in endometrial cancer—MMP-9 correlates to the grade and the stage, Gyn. Oncol., 94, 699, 10.1016/j.ygyno.2004.06.028

Talvensaari-Mattila, 2005, Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma, Cancer Lett.

Sehgal, 1998, Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma, Am. J. Pathol., 152, 591

Stearns, 1997, IL-10 inhibition of human prostate PC-3 Ml cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression, Invasion Metastasis, 17, 62

Stearns, 1999, Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion, Clin. Cancer Res., 5, 189

Upadhyay, 1999, Membrane type-1 matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization associated with high-grade prostatic intraepithelial neoplasia, Clinical Cancer Res., 5, 4105

Still, 2000, Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benine and malignant prostatic tissue, Prostate, 42, 18, 10.1002/(SICI)1097-0045(20000101)42:1<18::AID-PROS3>3.0.CO;2-A

Ross, 2003, Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer, Mod. Pathol., 16, 198, 10.1097/01.MP.0000056984.62360.6C

Stearns, 1996, Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP2a) expression in human prostate cancer, Onc. Res., 8, 63

Wood, 1997, In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer, Clin. Exp. Met., 15, 246, 10.1023/A:1018421431388

Lein, 1998, Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma, Urologe Ausgabe A, 37, 377, 10.1007/s001200050194

Gohji, 1998, Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension, Int. J. Cancer, 79, 96, 10.1002/(SICI)1097-0215(19980220)79:1<96::AID-IJC18>3.0.CO;2-F

Grignon, 1996, High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasine bladder cancer, Cancer Res., 56, 1654

Kanayama, 1998, Prognostic values of matrix metalloproteinase-2 and tissure inhibitor of metalloproteinase-2 expression in bladder cancer, Cancer, 82, 1359, 10.1002/(SICI)1097-0142(19980401)82:7<1359::AID-CNCR20>3.0.CO;2-4

Vasala, 2003, Matrix metalloproteainse-2 immunocreactive protein as a prognostic marker in bladder cancer, Urology, 62, 952, 10.1016/S0090-4295(03)00660-5

Gohji, 1996, Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma, Cancer, 7, 2379, 10.1002/(SICI)1097-0142(19961201)78:11<2379::AID-CNCR17>3.0.CO;2-Y

Gohji, 1998, Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer, Br. J. Cancer, 77, 650, 10.1038/bjc.1998.104

Walther, 1997, Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival, Urology, 50, 295, 10.1016/S0090-4295(97)00220-3

Kallakury, 2001, Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma, Clin. Cancer Res., 7, 3113

Nawrocki, 1977, Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantitative and morphological analysis, Int. J. Cancer, 72, 556, 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.0.CO;2-P

Brown, 1993, Association between expression of activated 72-kD gelatinase and tumor spread in non-small-cell lung carcinoma, J. Natl. Cancer Inst., 85, 574, 10.1093/jnci/85.7.574

Kodate, 1997, Expression of MMP (gelatinase) in T1 adenocarcinoma of the lung, Pathol. Int., 47, 461, 10.1111/j.1440-1827.1997.tb04525.x

Herbst, 2000, Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma, Clin. Cancer Res., 6, 790

Cox, 2000, Matrix metalloproteinase-9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer, Clin. Cancer Res., 6, 2349

Sienel, 2003, Prognostic impact of matrix metalloproteinase-9 in operable non small cell lung cancer, Int. J. Cancer, 103, 647, 10.1002/ijc.10841

Aljada, 2004, Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer, J. Clin. Oncol., 22, 3218, 10.1200/JCO.2004.02.110

Ylisirniö, 2000, Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer-TIMP-1 as a prognostic marker, Anticancer Res., 20, 1311

Franchi, 2002, Expression of matrix metalloproteinase 1, matrix metalloproteinase 2 and matrix metalloproteinase 9 in carcinoma of the head and neck. Correlation with p53 status inducible nitrix oxide synthase activity and angiogenesis, Cancer, 95, 1902, 10.1002/cncr.10916

Ruokolainen, 2004, Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma, a potential marker for prognosis, Clin. Cancer Res., 10, 3110, 10.1158/1078-0432.CCR-03-0530

Ranuncolo, 2002, Joffe'E Puricelli, Circulation 92-Kilodalton Matrix metalloproteainse (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma, Cancer, 94, 1483, 10.1002/cncr.10356

Levy, 1991, Increased expression of the mr. 72000 type IV collagenase in human colonic adenocarcinoma, Cancer Res., 51, 439

Ring, 1997, Expression of tissue inhibitor of metalloproteinase TIMP-2 in human colorectal cancer—a predictor of tumor stage, Br. J. Cancer, 76, 805, 10.1038/bjc.1997.466

Zeng, 1996, Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9, J. Clin. Oncol., 14, 3133, 10.1200/JCO.1996.14.12.3133

Yukawa, 2001, Plasma concentration of tissue inhibitor of matrix metalloproteinase-1 in patients with colorectal carcinoma, Br. J. Surg., 88, 1596, 10.1046/j.0007-1323.2001.01930.x

Grigioni, 1994, Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane, Mol. Pathol., 7, 220

Sier, 1996, Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma, Br. J. Cancer, 74, 413, 10.1038/bjc.1996.374

Zhang, 2003, Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiness and metastasis of human gastric carcinoma, World J. Gastroenterol., 9, 899, 10.3748/wjg.v9.i5.899

Yoshikawa, 1999, Tissue inhibitor of matrix metalloproteainse-1 in the plasma patients with gastric carcinoma. A possible marker for serosa invasion and metastasis, Cancer, 86, 1929, 10.1002/(SICI)1097-0142(19991115)86:10<1929::AID-CNCR8>3.0.CO;2-C

Yoshikawa, 2001, Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma: a new biomarker for invasion and its impact on survival, Cancer, 91, 1739, 10.1002/1097-0142(20010501)91:9<1739::AID-CNCR1192>3.0.CO;2-9

Bramhall, 1997, Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic cancer, J. Pathol., 18, 347, 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J

Hujanen, 1991, Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro, Int. J. Cancer, 47, 576, 10.1002/ijc.2910470416

Hendrix, 1990, Retinoic acid inhibitor of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor, Cancer Res., 50, 4121

Valente, 1998, TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis, Int. J. Cancer, 75, 246, 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B

Montgomery, 1994, Effect of tissue inhibitor of the matrix metalloproteinase-2 expression on the growth and spontaneous metastasis of a human melanoma cell line, Cancer Res., 54, 5467

Chirivi, 1994, Inhibition of the metastatic spread and growth of BI6-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor, Int. J. Cancer, 58, 460, 10.1002/ijc.2910580326

Hujanen, 1994, Modulation of Mr 72.000 and Mr 92.000 type IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma, Int. J. Cancer, 58, 582, 10.1002/ijc.2910580422

Väisänen, 1996, Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value, J. Pathol., 180, 283, 10.1002/(SICI)1096-9896(199611)180:3<283::AID-PATH662>3.0.CO;2-3

Väisänen, 1998, Prognostic value of MMP-2 immunocreative protein (72 kD type IV collagenase) in primary skin melanoma, J. Pathol., 186, 51, 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P

Väisänen, 1999, Matrix metalloproteinase-2 (MMP-2) immunocreative protein—a new prognostic marker in ureal melanoma?, J. Pathol., 188, 56, 10.1002/(SICI)1096-9896(199905)188:1<56::AID-PATH304>3.0.CO;2-B

Vuoristo, 2000, Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma, Acta Oncol., 39, 877, 10.1080/028418600750063659

Wollina, 2001, Serum matrix metalloproteainse-2 in patients with malignant melanoma, J. Cancer Res. Clin. Oncol., 127, 631, 10.1007/s004320100257

J. Nikkola, P. Vihinen, M.S. Vuoristo, P. Kellokumpu-Lehtinen, V.M. Kähäri, S. Pyrhönen, High serum levels of MMP-9 and MMP-1 are associated with rapid progression in patients with metastatic melanoma, Submitted for publication.

Levicar, 2003, Proteases in brain tumour progression, Acta Nueorchirurgica, 145, 825, 10.1007/s00701-003-0097-z

Bello, 2001, Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2, Cancer Res., 61, 8730

Takahashi, 2002, In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture, Pharmacol. Res., 46, 155, 10.1016/S1043-6618(02)00081-6

Rao, 1993, Elevated levels of Mr 92,000 type IV collagenase in human brain tumors, Cancer Res., 53, 2208

Nakagawa, 1994, Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors, J. Neurosurg., 81, 69, 10.3171/jns.1994.81.1.0069

Nakano, 1995, Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas, J. Neurosurg., 83, 298, 10.3171/jns.1995.83.2.0298

Saxena, 1995, Increased expression of gelatinase A and TIMP-2 in primary human glioblastomas, Int. J. Oncol., 7, 469

Rao, 1996, Expression and localization of 92 kDa type IV collagenase/gelatinaseB (MMP-9) in human gliomas, Clin. Exp. Metastasis, 14, 12, 10.1007/BF00157681

Sawaya, 1996, Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo, Clin. Exp. Metastasis, 14, 35, 10.1007/BF00157684

Friedberg, 1998, Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis, Cancer, 82, 923, 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2

Mohanam, 1995, Expression of tissue inhibitors of metalloproteinase: negative regulators of human glioblastoma invasion in vivo, Clin. Exp. Metastasis, 13, 57, 10.1007/BF00144019

Kachra, 1999, Expression of matrix metalloproteinases and their inhibitors in human brain tumors, Clin. Exp. Metastasis, 17, 555, 10.1023/A:1006760632766

Jäälinoja, 2000, Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms, J. Neuro-Ongology, 46, 81, 10.1023/A:1006421112839

Pagenstecher, 2001, Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors, J. Neuropathol. Exp. Neurol., 60, 598, 10.1093/jnen/60.6.598

Thorns, 2003, Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas, Anticancer Res., 23, 3937